Treatment of chronic myeloid therapy with tyrosine kinase inhibitors: drug toxicity and resistance to therapy
Abstract
The study was conducted to assess the incidence of tyrosine kinase inhibitors toxicity and resistance to first-line therapy of chronic myeloid leukemia. The results demonstrated that indications to prescription of the second generation tyrosine kinase inhibitors are mostly due to significant non-hematologic toxicity. Optimal response to therapy requires regular clinical and laboratory monitoring for early detection of drug intolerance and resistance to first-line therapy.
About the Authors
V. N. Yadrikhinskaya
North-Eastern Federal University named after M.K. Ammosov
Russian Federation
Russian Federation
Yakutsk
I. I. Mulina
RB No. 1-National Center of Medicine
Russian Federation
Russian Federation
Yakutsk
T. N. Aleksandrova
North-Eastern Federal University named after M.K. Ammosov
Russian Federation
Russian Federation
Yakutsk
A. N. Sannikova
RB No. 1-National Center of Medicine
Russian Federation
Russian Federation
Yakutsk
S. N. Parfenova
RB No. 1-National Center of Medicine
Russian Federation
Russian Federation
Yakutsk
A. M. Popova
RB No. 1-National Center of Medicine
Russian Federation
Russian Federation
Yakutsk
I. E. Soloveva
RB No. 1-National Center of Medicine
Russian Federation
Russian Federation
Yakutsk
References
1. Abdulkadyrov K.M. Dasatinib: 10 years of clinical practice worldwide / K.M. Abdulkadyrov, V.A. Shuvaev, I.S. Martynkevich // Oncohematology. – 2016. - № 1. – Vol. 11. – P. 24-33.
2. Tyrosine kinase inhibitors therapy related neutropenia and thrombocythopenia correction in CML patients/ V. A. Shuvaev, M. S. Fominykh, I. S. Martynkevich [et al.] // Oncohematology. – 2016. - № 4. – Vol. 8. – P. 7-12.
3. Assessment of adverse drug effects of targeted therapy in patients with chronic myeloid leukemia / M.I.Savelyeva, O.S. Samoylova, I.N. Samarina [et al.] // The Kremlin medicine. Clinical bulletin. – 2012. – № 2. – Р. 52-55.
4. Problems of the organization of chronic myeloid leukemia therapy in the Russian Federation/ O. Yu. Vinogradova, S.M. Kulikov, S.M. Kutsev// Clinical oncohematology. - 2011. - № 4. – Vol. 4. – P. 292-297.
5. Federal clinical recommendations for diagnosis and treatment of chronic myeloid leukemia / K.M. Abdulkadyrov, A.O. Abdullaev, L.B. Avdeeva [et al.] // Vestnik gematologii. – 2013. - № 3. – V. 9. – P. 4-43.
6. Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia / R. Hehlmann, U. Berger, M. Pfirrmann [et al.] // Blood. – 2007. - № 11. – Vol. 109. – P. 4686–92.
7. Hochhaus A. Dasatinib induces notable hematologic and cytogenetic responces in chronic phase CML after failure of imatinib / A. Hochhaus, M. Hagop Kantarjian., M. Baccarani // Blood. – 2007. – Vol. 109. – P. 2303-2309.
8. Imatinib compared with interferon and lowdose cytarabine for newly diagnosed chronicphase chronic myeloid leukemia / S.G. O’Brien, F. Guilhot, R. Larson R [et al.] // N Engl J Med. – 2003. – Vol. 348. – P. 994-1004.
9. Common Terminology Criteria for Adverse Events (CTCAE) v4.0. Publish date: May, 28, 2009, URL: https://evs.nci.nih.gov/ftp1/CTCAE.
Review
For citations:
Yadrikhinskaya V.N., Mulina I.I., Aleksandrova T.N., Sannikova A.N., Parfenova S.N., Popova A.M., Soloveva I.E. Treatment of chronic myeloid therapy with tyrosine kinase inhibitors: drug toxicity and resistance to therapy. Yakut Medical Journal. 2017;(2):62-64.
Views:
31
Email this article 